Pharmaceuticals

Impact Of Increasing Cancer Prevalence On The Bi-Specific MAbs Market Is Supporting Development Across The Bi-Specific MAbS Market

May 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Bi-Specific MAbS Market During The 2026–2030 Period?

The bi-specific mabs market has demonstrated rapid expansion in recent years. Its valuation is set to grow from $11.64 billion in 2025 to $13.16 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. Historically, this market expansion can be linked to the initial approval of bsabs therapies, an increasing occurrence of hematological cancers, the early uptake of monoclonal antibodies, greater investment in oncology research and development, and a surge in hospital-based clinical trials.

The bi-specific mabs market size is anticipated to undergo significant expansion over the coming years, projected to reach $21.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This forecasted growth is primarily driven by progress in integrating gene and cell therapies, an expanding pipeline of bsabs, increased research and development funding for rare diseases, the growing adoption of precision medicine, and the introduction of innovative bsabs delivery platforms. Key developments during this period are expected to encompass the broader application of tumor immunotherapy, the evolution of multi-targeted bi-specific antibodies, an upsurge in treatments for hemophilia and other rare conditions, advancements in in vitro and in vivo technologies, and a rise in strategic partnerships between pharmaceutical and biotechnology companies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What Influential Factors Are Boosting The Bi-Specific MAbS Market Demand?

The bispecific monoclonal antibodies market is projected to grow over the forecast period, driven by the increasing prevalence of cancer and other chronic diseases. These antibodies are developed for treating various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered more effective than monoclonal antibodies (moAbs) because they target two or more tumor antigens on cells, thereby disrupting cancer progression. For instance, in 2023, the Cancer Facts & Figures 2023 report by the American Cancer Society (ACS) estimated 609,820 cancer-related deaths in the USA. Therefore, the rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to effectively treat these conditions.

What Segment Types Are Included In The Bi-Specific MAbS Market Analysis?

The bi-specific mabs market covered in this report is segmented –

1) By Drug: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Which Trends Are Expected To Shape The Bi-Specific MAbS Market?

Leading companies in the bi-specific mAbs market are concentrating on technological breakthroughs, such as CD20 x CD3 T-cell engaging bispecific antibodies, to satisfy the increasing need for more potent, readily available immunotherapies in hematological malignancies that offer courses of treatment with set durations. A CD20 x CD3 bispecific antibody is engineered to position T cells close to B cells by binding to CD3 on T cells and CD20 on B cells, thereby initiating T-cell-mediated destruction of malignant B cells; unlike conventional monoclonal antibodies that target solely B cells (or only T-cell checkpoints), this design leverages immune effector function in a highly specific manner. For example, in June 2023, Roche AG, a Switzerland-based biopharmaceutical company, launched Columvi (glofitamab-gxbm), a CD20xCD3 bispecific T-cell engager. Columvi possesses a novel 2:1 structural format (two CD20-binding domains and one CD3-binding domain), is given as a fixed-duration (approximately 8.5-month) therapy, and is intended to provide durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Its fixed-duration regimen presents the possibility of a treatment-free period after therapy, distinguishing it from continuous treatment methods, and it has exhibited strong efficacy in clinical trials with a manageable safety profile.

Who Are The Firms Contributing To The Bi-Specific MAbS Market Ecosystem?

Major companies operating in the bi-specific mabs market are F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda Pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Sanofi S.A., Novo Nordisk A/S, Aspen Pharmacare, Baxter International

Access The Complete Bi-Specific MAbS Market Report:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Which Region Leads The Bi-Specific MAbS Market By Size?

North America was the largest region in the bi-specific MAbs market in 2025. The regions covered in the bi-specific mabs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Bi-Specific MAbS Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Browse Through More Reports Similar to the Global Bi-Specific MAbS Market 2026, By The Business Research Company

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Bi Specific Mab Market Report 2026

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Anti Cancer Mabs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795